NeueHealth, Inc.

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, SIRO has a market cap of 22B. Regarding current trading prices, NEUE is priced at $6.75, while SIRO trades at $109.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas SIRO's P/E ratio is N/A. In terms of profitability, NEUE's ROE is +0.09%, compared to SIRO's ROE of +0.14%. Regarding short-term risk, NEUE is less volatile compared to SIRO. This indicates potentially lower risk in terms of short-term price fluctuations for NEUE.Check SIRO's competition here

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, HIMS has a market cap of 6.1B. Regarding current trading prices, NEUE is priced at $6.75, while HIMS trades at $27.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas HIMS's P/E ratio is 54.76. In terms of profitability, NEUE's ROE is +0.09%, compared to HIMS's ROE of +0.23%. Regarding short-term risk, NEUE is less volatile compared to HIMS. This indicates potentially lower risk in terms of short-term price fluctuations for NEUE.Check HIMS's competition here

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, NVST has a market cap of 4.3B. Regarding current trading prices, NEUE is priced at $6.75, while NVST trades at $26.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas NVST's P/E ratio is 94.63. In terms of profitability, NEUE's ROE is +0.09%, compared to NVST's ROE of +0.02%. Regarding short-term risk, NEUE is less volatile compared to NVST. This indicates potentially lower risk in terms of short-term price fluctuations for NEUE.Check NVST's competition here

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, CON has a market cap of 2.9B. Regarding current trading prices, NEUE is priced at $6.75, while CON trades at $22.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas CON's P/E ratio is 17.49. In terms of profitability, NEUE's ROE is +0.09%, compared to CON's ROE of +0.47%. Regarding short-term risk, NEUE is less volatile compared to CON. This indicates potentially lower risk in terms of short-term price fluctuations for NEUE.Check CON's competition here

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, BBNX has a market cap of 449.2M. Regarding current trading prices, NEUE is priced at $6.75, while BBNX trades at $10.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas BBNX's P/E ratio is -7.36. In terms of profitability, NEUE's ROE is +0.09%, compared to BBNX's ROE of -0.23%. Regarding short-term risk, NEUE is less volatile compared to BBNX. This indicates potentially lower risk in terms of short-term price fluctuations for NEUE.Check BBNX's competition here

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, CV has a market cap of 337.9M. Regarding current trading prices, NEUE is priced at $6.75, while CV trades at $6.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas CV's P/E ratio is -6.58. In terms of profitability, NEUE's ROE is +0.09%, compared to CV's ROE of +1.05%. Regarding short-term risk, NEUE is less volatile compared to CV. This indicates potentially lower risk in terms of short-term price fluctuations for NEUE.Check CV's competition here

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, NAKA has a market cap of 70M. Regarding current trading prices, NEUE is priced at $6.75, while NAKA trades at $0.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas NAKA's P/E ratio is -0.72. In terms of profitability, NEUE's ROE is +0.09%, compared to NAKA's ROE of -0.21%. Regarding short-term risk, NEUE is less volatile compared to NAKA. This indicates potentially lower risk in terms of short-term price fluctuations for NEUE.Check NAKA's competition here

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, KDLY has a market cap of 68.1M. Regarding current trading prices, NEUE is priced at $6.75, while KDLY trades at $11.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas KDLY's P/E ratio is -15.48. In terms of profitability, NEUE's ROE is +0.09%, compared to KDLY's ROE of -0.21%. Regarding short-term risk, NEUE is less volatile compared to KDLY. This indicates potentially lower risk in terms of short-term price fluctuations for NEUE.Check KDLY's competition here

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, PARK has a market cap of 34.7M. Regarding current trading prices, NEUE is priced at $6.75, while PARK trades at $17.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas PARK's P/E ratio is -99.11. In terms of profitability, NEUE's ROE is +0.09%, compared to PARK's ROE of -67.96%. Regarding short-term risk, NEUE is less volatile compared to PARK. This indicates potentially lower risk in terms of short-term price fluctuations for NEUE.Check PARK's competition here

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, BRK has a market cap of 11.6M. Regarding current trading prices, NEUE is priced at $6.75, while BRK trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas BRK's P/E ratio is N/A. In terms of profitability, NEUE's ROE is +0.09%, compared to BRK's ROE of N/A. Regarding short-term risk, NEUE is less volatile compared to BRK. This indicates potentially lower risk in terms of short-term price fluctuations for NEUE.Check BRK's competition here

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, PFSA has a market cap of 309.2K. Regarding current trading prices, NEUE is priced at $6.75, while PFSA trades at $0.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas PFSA's P/E ratio is -0.01. In terms of profitability, NEUE's ROE is +0.09%, compared to PFSA's ROE of +0.82%. Regarding short-term risk, NEUE is less volatile compared to PFSA. This indicates potentially lower risk in terms of short-term price fluctuations for NEUE.Check PFSA's competition here

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, DSCI has a market cap of 0. Regarding current trading prices, NEUE is priced at $6.75, while DSCI trades at $7.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas DSCI's P/E ratio is N/A. In terms of profitability, NEUE's ROE is +0.09%, compared to DSCI's ROE of -0.00%. Regarding short-term risk, NEUE is more volatile compared to DSCI. This indicates potentially higher risk in terms of short-term price fluctuations for NEUE.Check DSCI's competition here

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, LPNT has a market cap of 0. Regarding current trading prices, NEUE is priced at $6.75, while LPNT trades at $64.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas LPNT's P/E ratio is N/A. In terms of profitability, NEUE's ROE is +0.09%, compared to LPNT's ROE of +0.05%. Regarding short-term risk, NEUE is more volatile compared to LPNT. This indicates potentially higher risk in terms of short-term price fluctuations for NEUE.Check LPNT's competition here

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, AMSG has a market cap of 0. Regarding current trading prices, NEUE is priced at $6.75, while AMSG trades at $67.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas AMSG's P/E ratio is N/A. In terms of profitability, NEUE's ROE is +0.09%, compared to AMSG's ROE of +0.08%. Regarding short-term risk, NEUE is less volatile compared to AMSG. This indicates potentially lower risk in terms of short-term price fluctuations for NEUE.Check AMSG's competition here

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, ABAX has a market cap of 0. Regarding current trading prices, NEUE is priced at $6.75, while ABAX trades at $83.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas ABAX's P/E ratio is N/A. In terms of profitability, NEUE's ROE is +0.09%, compared to ABAX's ROE of +0.10%. Regarding short-term risk, NEUE is more volatile compared to ABAX. This indicates potentially higher risk in terms of short-term price fluctuations for NEUE.Check ABAX's competition here

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, MEDC has a market cap of 0. Regarding current trading prices, NEUE is priced at $6.75, while MEDC trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas MEDC's P/E ratio is N/A. In terms of profitability, NEUE's ROE is +0.09%, compared to MEDC's ROE of N/A. Regarding short-term risk, NEUE is less volatile compared to MEDC. This indicates potentially lower risk in terms of short-term price fluctuations for NEUE.Check MEDC's competition here

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, COTV has a market cap of 0. Regarding current trading prices, NEUE is priced at $6.75, while COTV trades at $44.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas COTV's P/E ratio is N/A. In terms of profitability, NEUE's ROE is +0.09%, compared to COTV's ROE of +0.14%. Regarding short-term risk, NEUE is more volatile compared to COTV. This indicates potentially higher risk in terms of short-term price fluctuations for NEUE.Check COTV's competition here

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, EVHC has a market cap of 0. Regarding current trading prices, NEUE is priced at $6.75, while EVHC trades at $45.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas EVHC's P/E ratio is N/A. In terms of profitability, NEUE's ROE is +0.09%, compared to EVHC's ROE of +0.07%. Regarding short-term risk, NEUE is more volatile compared to EVHC. This indicates potentially higher risk in terms of short-term price fluctuations for NEUE.Check EVHC's competition here

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, CYNO has a market cap of 0. Regarding current trading prices, NEUE is priced at $6.75, while CYNO trades at $66.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas CYNO's P/E ratio is N/A. In terms of profitability, NEUE's ROE is +0.09%, compared to CYNO's ROE of +0.03%. Regarding short-term risk, NEUE is more volatile compared to CYNO. This indicates potentially higher risk in terms of short-term price fluctuations for NEUE.Check CYNO's competition here

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, SPAN has a market cap of 0. Regarding current trading prices, NEUE is priced at $6.75, while SPAN trades at $29.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas SPAN's P/E ratio is N/A. In terms of profitability, NEUE's ROE is +0.09%, compared to SPAN's ROE of +0.17%. Regarding short-term risk, NEUE is less volatile compared to SPAN. This indicates potentially lower risk in terms of short-term price fluctuations for NEUE.Check SPAN's competition here

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, EXAC has a market cap of 0. Regarding current trading prices, NEUE is priced at $6.75, while EXAC trades at $49.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas EXAC's P/E ratio is N/A. In terms of profitability, NEUE's ROE is +0.09%, compared to EXAC's ROE of +0.00%. Regarding short-term risk, NEUE is more volatile compared to EXAC. This indicates potentially higher risk in terms of short-term price fluctuations for NEUE.Check EXAC's competition here

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, SCAI has a market cap of 0. Regarding current trading prices, NEUE is priced at $6.75, while SCAI trades at $55.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas SCAI's P/E ratio is N/A. In terms of profitability, NEUE's ROE is +0.09%, compared to SCAI's ROE of +0.09%. Regarding short-term risk, NEUE is more volatile compared to SCAI. This indicates potentially higher risk in terms of short-term price fluctuations for NEUE.Check SCAI's competition here

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, LDR has a market cap of 0. Regarding current trading prices, NEUE is priced at $6.75, while LDR trades at $67.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas LDR's P/E ratio is N/A. In terms of profitability, NEUE's ROE is +0.09%, compared to LDR's ROE of +1.17%. Regarding short-term risk, NEUE is more volatile compared to LDR. This indicates potentially higher risk in terms of short-term price fluctuations for NEUE.Check LDR's competition here

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, ABCO has a market cap of 0. Regarding current trading prices, NEUE is priced at $6.75, while ABCO trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas ABCO's P/E ratio is N/A. In terms of profitability, NEUE's ROE is +0.09%, compared to ABCO's ROE of +0.19%. Regarding short-term risk, NEUE is more volatile compared to ABCO. This indicates potentially higher risk in terms of short-term price fluctuations for NEUE.Check ABCO's competition here

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, SPNC has a market cap of 0. Regarding current trading prices, NEUE is priced at $6.75, while SPNC trades at $38.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas SPNC's P/E ratio is N/A. In terms of profitability, NEUE's ROE is +0.09%, compared to SPNC's ROE of -0.61%. Regarding short-term risk, NEUE is more volatile compared to SPNC. This indicates potentially higher risk in terms of short-term price fluctuations for NEUE.Check SPNC's competition here

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, MZOR has a market cap of 0. Regarding current trading prices, NEUE is priced at $6.75, while MZOR trades at $58.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas MZOR's P/E ratio is N/A. In terms of profitability, NEUE's ROE is +0.09%, compared to MZOR's ROE of -0.14%. Regarding short-term risk, NEUE is more volatile compared to MZOR. This indicates potentially higher risk in terms of short-term price fluctuations for NEUE.Check MZOR's competition here

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, PMC has a market cap of 0. Regarding current trading prices, NEUE is priced at $6.75, while PMC trades at $29.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas PMC's P/E ratio is N/A. In terms of profitability, NEUE's ROE is +0.09%, compared to PMC's ROE of +0.04%. Regarding short-term risk, NEUE is more volatile compared to PMC. This indicates potentially higher risk in terms of short-term price fluctuations for NEUE.Check PMC's competition here

NEUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEUE stands at 60.9M. In comparison, STJ has a market cap of 0. Regarding current trading prices, NEUE is priced at $6.75, while STJ trades at $80.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEUE currently has a P/E ratio of -0.38, whereas STJ's P/E ratio is N/A. In terms of profitability, NEUE's ROE is +0.09%, compared to STJ's ROE of +0.21%. Regarding short-term risk, NEUE is more volatile compared to STJ. This indicates potentially higher risk in terms of short-term price fluctuations for NEUE.Check STJ's competition here